Nabriva Therapeutics AG (NBRV) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Nabriva Therapeutics AG (NASDAQ:NBRV) from a hold rating to a sell rating in a report issued on Wednesday morning.

According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “

NBRV has been the topic of several other reports. Needham & Company LLC reaffirmed a buy rating and set a $15.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, March 27th. Cantor Fitzgerald reaffirmed a buy rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Tuesday, April 11th. HC Wainwright reaffirmed a buy rating on shares of Nabriva Therapeutics AG in a report on Friday, May 12th. Wedbush reaffirmed an outperform rating and set a $13.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. Finally, ValuEngine raised Nabriva Therapeutics AG from a sell rating to a hold rating in a report on Saturday, June 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $15.29.

Shares of Nabriva Therapeutics AG (NBRV) opened at 10.35 on Wednesday. The firm’s 50 day moving average price is $9.87 and its 200-day moving average price is $9.52. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $12.75. The company’s market capitalization is $28.16 million.

WARNING: “Nabriva Therapeutics AG (NBRV) Rating Lowered to Sell at Zacks Investment Research” was originally posted by Stock Observer and is owned by of Stock Observer. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.thestockobserver.com/2017/07/18/nabriva-therapeutics-ag-nbrv-rating-lowered-to-sell-at-zacks-investment-research.html.

In other news, Director George Harrison Talbot sold 325 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $100.56, for a total value of $32,682.00. Following the transaction, the director now owns 3,854 shares in the company, valued at $387,558.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Hbm Healthcare Investments (Ca sold 23,932 shares of the firm’s stock in a transaction that occurred on Thursday, April 20th. The shares were sold at an average price of $11.11, for a total value of $265,884.52. Following the completion of the transaction, the insider now owns 2,624,633 shares in the company, valued at approximately $29,159,672.63. The disclosure for this sale can be found here. Insiders have sold 126,778 shares of company stock worth $1,453,057 in the last quarter.

Several institutional investors have recently added to or reduced their stakes in the stock. Almanack Investment Partners LLC. purchased a new position in Nabriva Therapeutics AG during the first quarter valued at $1,870,000. Wellington Management Group LLP increased its position in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the period. Nationwide Fund Advisors purchased a new position in Nabriva Therapeutics AG during the first quarter valued at $2,074,000. Finally, Renaissance Technologies LLC purchased a new position in Nabriva Therapeutics AG during the fourth quarter valued at $103,000. Institutional investors and hedge funds own 56.73% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).

Get a free copy of the Zacks research report on Nabriva Therapeutics AG (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply